Compare Biogen Inc (BIIB) vs Western Union Co (WU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Western Union Co — how do they compare? Biogen Inc trades at $193.68 (market cap $28.34B), while Western Union Co trades at $8.02 (market cap $2.46B). The key difference: Biogen Inc is far larger — about 11.5× Western Union Co's market cap, and Western Union Co pays a 11.93% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BIIB | WU | |
|---|---|---|
Market Cap | $28.34B | $2.46B |
Sector | Health | Technology |
52-Week High | $216.63 | $10.28 |
52-Week Low | $122.68 | $7.04 |
Enterprise Value | $30.62B | $2.16B |
Dividend Yield | — | 11.93% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $209.03, up 4.96% today, with a bullish technical signal and strong analyst support. Recent quarterly earnings have consistently beaten expectations, and the company maintains solid profitability with a 75.49% gross margin. Key developments include FDA approval for a subcutaneous starter dose of Leqembi and promising Phase 2 data for its Alzheimer's drug diranersen, driving positive sentiment.
The outlook is positive, with a consensus price target of $230.18 suggesting upside. Investment opportunities lie in Alzheimer's pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Revenue stability and cost management support fundamentals, though regulatory hurdles remain a watchpoint.
Western Union (WU) trades at $7.87, up 0.38% with a bullish technical signal. The stock shows attractive valuation with P/E of 5.79 and P/S of 0.63, supported by strong profitability metrics including 47.66% ROE. Recent earnings show mixed performance with Q1 2026 miss but Q3 and Q4 2025 beats. The company maintains strategic partnerships with Total Wireless and digital expansion initiatives, though revenue has declined from $4.5B in 2022 to $4.05B in 2025.
WU presents a value opportunity with deep valuation discounts but faces revenue headwinds and competitive pressures. The 11.5% dividend yield provides income support, though high debt levels and declining net income margins warrant caution. Analyst consensus remains mixed with 58% hold ratings, reflecting balanced risk-reward amid digital transformation efforts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Western Union Co
Western Union provides domestic and international money transfers through its global network of about 500,000 outside agents. It is the largest money transfer company in the world and one of only a few companies with a truly global agent network.
Read more on WU →
